Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT04061772
- Locations
- π¨π³
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
- Conditions
- Sarcoma
- Interventions
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 9
- Registration Number
- NCT04052334
- Locations
- πΊπΈ
Moffitt Cancer Center, Tampa, Florida, United States
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
- Conditions
- GlioblastomaMedulloblastomaEpendymomaDiffuse Intrinsic Pontine Glioma
- Interventions
- Drug: IndoximodDrug: TemozolomideRadiation: Partial RadiationRadiation: Full-dose RadiationDrug: CyclophosphamideDrug: EtoposideDrug: Lomustine
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Theodore S. Johnson
- Target Recruit Count
- 140
- Registration Number
- NCT04049669
- Locations
- πΊπΈ
Augusta University, Georgia Cancer Center, Augusta, Georgia, United States
πΊπΈEmory University, Children's Heathcare of Atlanta, Druid Hills, Georgia, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Conditions
- Lymphoblastic Lymphoma, Childhood
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 683
- Registration Number
- NCT04043494
- Locations
- π³π±
Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands
π«π·UnitΓ© d'hΓ©matologie pΓ©diatrique CHRU de Lille - HΓ΄pital Jeanne de Flandre, Lille, France
π§πͺUZ Antwerpen Kinderhemato-oncologie, Edegem, Belgium
CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.
- Conditions
- Leukemia Lymphocytic Acute (ALL) in RelapseLeukemia Lymphocytic Acute (All) RefractoryLymphoma, B-CellCD19 Positive
- Interventions
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04037566
- Locations
- π¨π³
Xijing Hospital, Xi'an, Shannxi, China
COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
- Conditions
- Estrogen Receptor-positive Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- University of Virginia
- Registration Number
- NCT04038489
- Locations
- πΊπΈ
University of Virginia, Charlottesville, Virginia, United States
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 647
- Registration Number
- NCT04031703
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
- Conditions
- Non-Hodgkin's Lymphoma, RelapsedChronic Lymphoid Leukemia in RelapseNon-Hodgkin's Lymphoma RefractoryChronic Lymphocytic LeukemiaLymphoma, Non-HodgkinLeukemia, Lymphocytic, ChronicB-cell Chronic Lymphocytic LeukemiaB-cell Non Hodgkin LymphomaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Precision BioSciences, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04030195
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
πΊπΈStanford University, Stanford, California, United States
πΊπΈCleveland Clinic, Cleveland, Ohio, United States
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
- Conditions
- CD22 PositiveProgressive DiseaseRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin LymphomaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRefractory Non-Hodgkin LymphomaCD19 PositiveMinimal Residual Disease
- Interventions
- Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cellsDrug: CyclophosphamideDrug: Fludarabine
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04029038
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
- Conditions
- Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Solid TumorsNeuroblastoma
- Interventions
- Drug: IdasanutlinDrug: FludarabineDrug: VenetoclaxDrug: CyclophosphamideDrug: TopotecanDrug: CytarabineDrug: Intrathecal Chemotherapy
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT04029688
- Locations
- πΊπΈ
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
πΊπΈLucile Packard Children's Hospital at Stanford University; Thoracic Oncology, Palo Alto, California, United States
πΊπΈArnold Palmer Hosp-Children, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.